GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.
PMID:3290715
| Citation |
Khatri, BO (1988) Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros. Neurology 38:50-2 |
|---|---|
| Abstract |
Based on the assumptions that multiple sclerosis (MS) is an autoimmune disorder and that plasmapheresis (PP) is an effective means of removing antibodies and other proteins from the circulation, several uncontrolled studies were undertaken to ascertain the role of PP in MS. Since MS is a chronic and persistent rather than monophasic illness, PP has been used in MS in conjunction with a variety of immunosuppressive drug regimens, theoretically to prevent the rebound reformation of the offending protein being removed. Careful analysis of the uncontrolled studies shows wide variance in the types of patients treated; the extent, duration and activity of their disease; and the methodology of PP and the adjunctive immunosuppressive treatment. Nevertheless, the conclusion we reached from this analysis was that prolonged treatment with PP, in conjunction with corticosteroid and other immunosuppressive drug treatment, may have a major clinical effect in patients severely disabled with chronic progressive MS. This in itself is a remarkable conclusion, since it is drawn from data about a form of MS which, by definition, rarely if ever improves spontaneously: more than one-half of the patients reported improvement. |
| Links | |
| Keywords |
Adult; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Male; Multiple Sclerosis/physiopathology; Multiple Sclerosis/therapy; Plasmapheresis/adverse effects |
| edit table |
Significance
Annotations
| Gene product | Qualifier | GO Term | Evidence Code | with/from | Aspect | Extension | Notes | Status |
|---|---|---|---|---|---|---|---|---|
|
Contributes to |
GO:0000166: nucleotide binding |
ECO:0000314: |
F |
The RNA binding region of RBMX is really important for HR. However, it is not for DNA lesions. This tells us that RBMX promotes HR trough protein expression due to splicing events. The PCR results shows that RBMX siRNAs also decreases BRCA2 levels in a manner that siRNA-resistant FHA-RBMX is involve (Figure 6d-e). RBMX does not have an effect on PALB2, BRCA1 and RPA2. The graph shown in Figure 4.a. tells us that RBMX acts as a recruiter. Hence, it is needed for resistance to DNA damage since it will recruit all the factors necessary for DNA damage repair. When RBMX leaves, it accumulates at sites of DNA in a poly (ADP-Ribose) polymerase (PARP1) dependent manner called anti-stripe (Figure 4 b-c). |
complete | |||
Notes
See also
References
See Help:References for how to manage references in GONUTS.
